Humanigen Inc (HGENQ)

[georgie18]

HGEN...$16.81...in the P/M...BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that management will host a conference call and webcast today at 8am ET to discuss topline results from the Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19...:party:

Details for the upcoming conference are below:

Webcast link: https://78449.themediaframe.com/dataconf/productusers/hmg/mediaframe/44119/indexl.html

Dial by phone: U.S. 877-405-1224 or Int’l: 201-389-0848.

The webcast will be archived for 90 days under the Investor Relations section of the company’s website at www.humanigen.com. ...
[6:38 AM]
georgie18 — 03/25/2021
HGEN...$13.50 in the P/M...Added late afternoon on the Lower Keltner Line Dip...:party: